To elucidate the action of polydatin in the development of steatohepatitis, we first used a genetic mutation model (db/db mice), which has a point mutation in leptin receptor, and fed MCD diet to mimic the pathogenesis and aetiology of human NASH.22, 23 We demonstrated that oral gavage of polydatin (100 mg/kg) every other day for 4 weeks reduced NAFLD activity score 21, 24 (Figure 1A,B) as well as liver levels of triglyceride (Figure 1C) accompanied by reduced liver levels of cholesterol (Figure 1D). This evidence concerns the gene LEPR and metabolic dysfunction-associated steatotic liver disease.